1. Roehrborn C. BPH progression: concept and key learning from MTOPS (Suppl 3): 17–21.
2. Marberger M, Harkaway R, de la Rosette J. Optimising the medical management of benign prostatic hyperplasia. Eur Urol 2004; 45: 411–9.
3. Speakman MJ, Kirby RS, Joyce A et al. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 2004; 93: 985–90.
4. Hutchison A, Farmer R, Verhamme et al. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 2007; 51: 207–16.
5. Abrams P, Wein AJ. The overactive bladder: from basic science to clinical management. Urology 1997; 50 (Suppl 6A): 1–144.
6. Irwin DE, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50: 1306–15.
7. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 2006; 49: 651–9.
8. Oelke M, Baard J, Wijkstra H et al. Age and Bladder Outlet Obstruction Are Independently Associated with Detrusor Overactivity in Patients with Benign Prostatic Hyperplasia. Eur Urol 2008; 54: 419–26.
9. de Nunzio C, Franco G, Rocchegiani A et al. The evolution of detrusor overactivity after watchful waiting, medical therapy and surgery in patients with bladder outlet obstruction. J Urol 2003; 169: 535–9.
10. Thomas AW, Cannon A, Bartlett E et al. The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up. BJU Int 2004; 93: 745–50.
11. Athanasopoulos A. The Role of Antimuscarinics in the Management of Men With Symptoms of Overactive Bladder Associated With Concomitant Bladder Outlet Obstruction: An Update. Eur Urol 2011. http://www.doi:10.1016/ j.eururo. 2011.03.054
12. Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005; 174: 2273–6.
13. Lee JY, Kim HW, Lee SJ et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004; 94: 817–20.
14. Blake-James BT, Rashidian A, Ikeda Y, Emberton M. The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 2006; 99: 85–96.
15. McGuire EJ, Savastano JA. Effect of alphaadrenergic blockade and anticholinergic agents on the decentralized primate bladder. Neurourol Urodyn 1985; 4: 139.
16. Steven A. Kaplan MD, Claus G et al. Tolterodine and Tamsulosin for Treatment of Men With Lower Urinary Tract Symptoms and Overactive Bladder. A Randomized Controlled Trial. JAMA 2006; 296: 2319–28.
17. Gravas S, Melekos MD. Male lower urinary tract symptoms: How do symptoms guide our choice of treatment? Curr Opin Urol 2009; 19 (1): 49–54.
18. Oelke M, Bachmann A, Descazeaud A et al. Guidelines on Conservative Treatment of Nonneurogenic Male LUTS. Update March 2011. European Association of Urology 2011.
19. Lee SH, Chung BH, Kim SJ et al. Bucheon, Initial Combined Treatment with Anticholinergics and Alpha-blockers for Men with Overactive Bladder and Bladder Outlet Obstraction Secondary to Benign Prostatic Hyperplasia: a Prospective Randomized Multicenter double-blind Placebo-controlled Study 2011; 185 (Suppl. 4).
20. Kaplan SA, McCammon K, Fincher R et al. Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency. J Urol 2009; 182: 2825–30.

П.И.Раснер, Д.Ю.Пушкарь 

Кафедра урологии ГОУ ВПО Московский государственный медико-стоматологический университет Минздравсоцразвития РФ